Skip to main content
. 2021 May 24;34(1):171–179. doi: 10.1111/den.14010

Figure 4.

Figure 4

Patients’ tolerability and adverse events. Group A: elobixibat 10 mg + PEG‐Asc 1 L. Group B: sodium picosulfate 20 mL + PEG‐Asc 1 L. PEG‐Asc: polyethylene glycol formulation containing ascorbic acid. Results are presented as mean ± standard deviation or number of patients.